Saniona A/s

Contera Pharma Aps

Contera Pharma A/s

Conrig Pharma Aps

Mikael S Thomsen

Peter G Nielsen

Bent Højgaard

John Bondo Hansen

Niels Skjaerbaek

Jens Damsgaard Mikkelsen

Mads Kreilgaard

Niels Skjærbæk

Peter Gudmund Nielsen

Jens D Mikkelsen

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.

Tesofensine and beta blocker combination formulations

Provided is a composition comprising suplatast tosilate or pharmaceutically acceptable derivatives thereof for use in a method of treating cough associated with interstitial lung disease, such as cough associated with pulmonary fibrosis.

Suplatast tosilate for use in the treatment of cough associated with interstitial lung disease

The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.

Use of buspirone metabolites

The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention.

Combinations of serotonin receptor agonists for treatment of movement disorders

The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.

Orally available pharmaceutical formulation suitable for improved management of movement disorders

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.

Growing community of inventors

Hvidovre, Denmark

Mikael S Thomsen